Skip to main content
. 2015 Apr 22;194(11):5497–5508. doi: 10.4049/jimmunol.1401218

FIGURE 8.

FIGURE 8.

ADCML activity of hIgG1 Fc-engineered variants. (A) ADCML activity measured against high-haptenated SRBCs in the presence of titrated amounts (900.0–3.7 ng/ml) of WT hIgG1 and Fc-engineered variants. (B) Histogram showing relative ADCML activity of the hIgG1 variants against high-haptenated SRBCs. (C) ADCML activity against low-haptenated SRBCs in the presence of titrated amounts (900.0–3.7 ng/ml) of WT hIgG1 and Fc-engineered variants. (D) Histogram showing relative ADCML activity of the hIgG1 variants against low-haptenated SRBCs. Experiments were performed at pH 7.4 and results are shown as mean ± SEM of one experiment performed in triplicate (A and C), and as mean ± SEM of three independent experiments performed in triplicate (B and D). ***p < 0.001 by one-way ANOVA test.